FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is a group if inventions: a pharmaceutical composition, containing immunologically active enantiomer of a component of the cationic lipid R-DOTAP or S-DOTAP, a method of applying the said enantiomer for induction of an immunostimulating adjuvant effect in the immune system, a method of inducing immune response in a patient with applying thereof and a method of treatment or prevention of a disease in the patient by induction of the immunostimulating adjuvant effect by the lipid.
EFFECT: R-DOTAP and S-DOTAP induced production of cytokines IL-2, IL-8, IL-12, chemokines CCL-5, CCL-19 and tumour regression in mice.
23 cl, 15 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE COMPOSITIONS WITH CATION LIPIDES AND METHODS OF APPLICATION | 2013 |
|
RU2649365C2 |
| USE OF MONOMYCOLYL GLYCEROL (MMG) AS ADJUVANT | 2008 |
|
RU2479317C2 |
| SPHINGOID POLYALKYLAMINE CONJUGATES FOR BACTERINATION | 2004 |
|
RU2361577C2 |
| STABLE COMPOSITIONS OF LIPIDS AND LIPOSOMES | 2015 |
|
RU2738060C2 |
| COMPOSITION OF LIPID VESICLES AND METHODS OF APPLICATION | 2011 |
|
RU2595872C2 |
| IMMUNOGENIC COMPOSITION AND METHOD OF FUSED PROTEIN VACCINE DEVELOPMENT | 2004 |
|
RU2407749C2 |
| IMMUNOSTIMULATING G,U-CONTAINING OLYGORIBONUCLEOTIDES | 2003 |
|
RU2302865C2 |
| MODULAR PARTICLES FOR IMMUNOTHERAPY | 2014 |
|
RU2672055C2 |
| COMBINATION OF ANTI-CANCER RNA VACCINE AND PD-1 PATHWAY INHIBITOR AND ITS APPLICATION | 2014 |
|
RU2718988C2 |
| EMULSIONS OF “OIL-IN-WATER” TYPE, WHICH CONTAIN NUCLEIC ACIDS | 2012 |
|
RU2606846C2 |
